Galectin Therapeutics Granted Patents in China and Japan that Support NASH and Cancer Immunotherapy Clinical Development ProgramsJanuary 25, 2018 | Press Release
Galectin Therapeutics Announces $10 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures into 2019December 19, 2017 | Press Release
A general overview of the company's activities and Clinical Phase studies with the Galectin-3 inhibitor GR-MD-02.
A detailed review of the results of the NASH-CX Clinical Trial.
A detailed review of the use of GR-MD-02 in combination therapy with KEYTRUDA in advanced melanoma.